May 28, 2025
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
Apr 21, 2025
The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
Feb 27, 2025
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
Dec 06, 2024
Supporting Health Equity: EpiVax Highlights Partnerships and New Research from Clínica Esperanza and GAIA Vaccine Foundation
Oct 24, 2024
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
Apr 01, 2024
Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development
Dec 15, 2020
EpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)
Dec 23, 2019
EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020
Dec 20, 2019
On Eve of New Decade, EpiVax Re-Pledges Commitment to Improving Health Everywhere
Nov 06, 2019
EpiVax Announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports
Oct 22, 2019
Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment
Oct 02, 2018
Office of Generic Drugs (OGD/FDA) Awards $1M FDA Contract to CUBRC and EpiVax for Demonstration and Validation of Immunogenicity Risk Assessment Methods for Generic Peptide Drugs and Their Impurities
Dec 19, 2017
EpiVax Announces NIH-Funded Grant To Develop New Graves' Disease Therapy
Sep 25, 2017
EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology
Sep 18, 2017
$5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect Against Bird Flu, A Collaboration Led By EpiVax
Aug 03, 2017
EpiVax Awarded "Innovation Voucher" to Accelerate the Development of a Game Changing Cancer Therapy